Shares of VBI Vaccines Inc (NASDAQ:VBIV) have been given an average rating of “Hold” by the five research firms that are presently covering the company, Marketbeat reports. Two analysts have rated the stock with a sell rating and three have issued a buy rating on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $12.00.
VBIV has been the subject of several analyst reports. Zacks Investment Research upgraded VBI Vaccines from a “sell” rating to a “hold” rating in a research note on Thursday, July 26th. BMO Capital Markets reduced their price objective on VBI Vaccines from $13.00 to $12.00 and set an “outperform” rating for the company in a research note on Friday, July 27th. Finally, ValuEngine upgraded VBI Vaccines from a “hold” rating to a “buy” rating in a research note on Thursday.
Hedge funds have recently modified their holdings of the business. Jane Street Group LLC purchased a new stake in VBI Vaccines in the 2nd quarter worth $331,000. Paloma Partners Management Co purchased a new stake in VBI Vaccines in the 2nd quarter worth $254,000. Altshuler Shaham Ltd increased its stake in VBI Vaccines by 11.5% in the 2nd quarter. Altshuler Shaham Ltd now owns 891,442 shares of the biopharmaceutical company’s stock worth $2,452,000 after buying an additional 91,800 shares in the last quarter. Alpine Global Management LLC purchased a new stake in VBI Vaccines in the 2nd quarter worth $222,000. Finally, Dimensional Fund Advisors LP purchased a new stake in VBI Vaccines in the 2nd quarter worth $223,000. Institutional investors and hedge funds own 48.00% of the company’s stock.
NASDAQ VBIV opened at $2.05 on Wednesday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 2.69 and a current ratio of 2.75. VBI Vaccines has a 1-year low of $1.64 and a 1-year high of $5.10.
About VBI Vaccines
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus.
Read More: Do Tariffs Work?
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.